Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Strategies for treating and managing testicular cancer.

  • Comment

Testicular cancer is a malignancy that differs from most others because of its extremely favourable prognosis. The cure rate approaches 100% in early stage disease and is still over 80% at the advanced stage, although survival decreases with increased age (Jones and Vasey, 2003a; Scholz and Holtl, 2003). On the whole testicular cancer is a disease that strikes young men, often during their most productive years (Rudberg et al, 2002).

Abstract

VOL: 102, ISSUE: 11, PAGE NO: 28

Ruth Dunleavey, BSc, RGN, is clinical research nurse, St Vincent’s Hospital, Sydney, Australia

Testicular cancer is a malignancy that differs from most others because of its extremely favourable prognosis. The cure rate approaches 100% in early stage disease and is still over 80% at the advanced stage, although survival decreases with increased age (Jones and Vasey, 2003a; Scholz and Holtl, 2003). On the whole testicular cancer is a disease that strikes young men, often during their most productive years (Rudberg et al, 2002).

 

 

Most (95%) testicular cancers are germ cell cancers (they arise from the ‘reproductive cells’ within the testis). The other 5% arise from supporting structures such as the sex cord, stromal cells or blood cells as in the case of leukaemia or lymphoma (Kundra, 2004). Each year in the UK 1,400 new germ cell tumours are diagnosed (Dearnley and Huddart, 2001).

 

 

Testicular cancer accounts for 1% of cancer in males but is the most common cancer in males aged 15-34.

 

 

Presentation
Testicular cancer usually presents as a painless enlargement in one testis. A normal testis is homogenous in consistency and freely moveable. Any nodular, hard or fixed area in the testis must be considered neoplastic until proven otherwise. There may be abdominal pain with large retroperitoneal metastases. Acute pain is rare unless there is concomitant epididymitis. One in ten men report a history of testicular trauma (Kundra, 2004).

 

 

Testicular cancer may be preceeded by carcinoma in situ (CIS) which is asymptomatic. About 5% of testis cancer patients will have CIS in their contralateral testis. This progresses to invasive cancer in 50% of cases (Holzbeierlein et al, 2003). If CIS is diagnosed (through biopsy), prophylactic radiotherapy may be implemented (Jones and Vasey, 2003).

 

 

Causation and risk factors
Although testicular cancer has a genetic component, incidence of a positive family history is as low as 2%. However, brothers of men with testicular cancer are 6-10 times more likely to develop the disease (Dearnley and Huddart, 2001). All cases share alterations on chromosome 12 and the disease may be caused by a combination of genetic and environmental factors. The age distribution of the disease suggests a prenatal initiating event followed by tumour development from adolescence. Cryptorchidism (undescended testes in childhood) is the only confirmed risk factor.

 

 

Histology
Ultrasound is the imaging modality of choice and is generally diagnostic. CT scanning is not used diagnostically but may be used to establish whether there is metastatic disease (Kundra, 2004). A full histological diagnosis is generally not made until an orchidectomy has been performed. Germ cell cancers are almost equally differentiated into seminoma and non-seminoma (Jones and Vasey 2003a) (Table 1).

 

 

The other main diagnostic feature is elevation of the tumour markers human chorionic gonadotrophin (HCG) and alpha fetoprotein (AFP). Concentrations of AFP are raised in 50-60% of non-seminomatous tumours (but not in pure seminomas). HCG is elevated in 30-35% of non-seminomatous tumours and 10-15% of seminomas (Dearnley and Huddart, 2001).

 

 

Lactic dehydrogenase (LDH) is also considered to be an indicator of tumour burden, growth rate and cellular proliferation.

 

 

Staging
Staging involves scanning the abdomen and chest to assess for the presence of metastatic disease. CT scanning may be associated with false positives and negatives and therefore some practitioners advocate MRI scanning, certainly in cases where the patient cannot take contrast.

 

 

Management
The first line of management is surgical. An orchidectomy is performed. A prosthetic testicle may be inserted and also a biopsy of the contralateral testicle may be considered at this stage to detect CIS. If tumour markers have been elevated pre-surgery, they should normally fall in the following days. The half-life of AFP is five days and of HCG is one to two days.

 

 

Management strategies can then be divided into:

 

 

- Management of non-seminomas;

 

 

- Management of seminomas.

 

 

This can be further divided into management of early and advanced disease. Testicular cancer is characterised by being highly curable whether in its early stages or if it has metastasised - even for advanced disease the cure rate can be approximately 80% among patients with a good prognosis (Scholz and Holtl, 2003). Among those with a poor prognosis survival falls to around 50% (Miki and Nakao, 2002).

 

 

Non-seminoma - early stage
The physician is faced with three options following surgery - survival is close to 100% whichever strategy is taken (Dearnley and Huddart, 2001).

 

 

Retroperitoneal lymph node dissection

 

 

Approximately 30% of patients who have stage 1 disease will have or will go on to develop retroperitoneal nodal involvement, usually within six months of orchidectomy (Scholz and Holtl, 2003).

 

 

The German Testicular Study Group published data on the complications associated with retroperitoneal lymph node dissection (RPLND) (Heidenrich et al, 2003). Of these complications, 19.7% were minor (superficial wound infection, intestinal paralysis, lymphocele) and 5.4% were major (chylous ascites, pulmonary embolism, hydronephrosis, small bowel obstruction). A proportion of patients may also experience infertility due to ejaculatory failure, although more modern surgical techniques have substantially reduced this (Rudberg et al, 2002).

 

 

Surveillance

 

 

Surveillance with no further treatment unless the patient relapses is the current standard in the UK. For 70% of patients this is ideal because they will require no further treatment and are effectively cured. Conversely 30% of patients will relapse in a median time of five to six months. Chemotherapy is as efficacious if given in relapse as if it is given adjuvantly post surgery and generally three or four courses will be required.

 

 

Surveillance needs to be rigorous. Current UK guidelines recommend three-monthly CT scans of chest and abdomen in the first year and one at the end of the second. Regular clinic visits are also required with chest X-ray and tumour marker analysis (Jones and Vasey, 2003a).

 

 

After the initial two-year period follow-up is still required although late relapse (after two years) occurs in only 2-3% of cases (Vaughn et al, 2002). Many testicular cancer patients will be followed in the long term by their GP, only seeing their oncologist annually after year five.

 

 

The principal prognostic indicator of relapse is vascular invasion of the tumour. Half of primary tumours are associated with vascular invasion (Dearnley and Huddart, 2001). Approximately 35-65% of tumours with vascular invasion managed by orchidectomy alone will develop recurrent disease (Scholz and Holtl, 2003). Histological type and tumour size may also be of prognostic significance according to some series (Scholz and Holtl, 2003).

 

 

Chemotherapy

 

 

BEP (bleomycin, etoposide, cisplatin) chemotherapy is the regimen of choice for early disease. As an adjuvant treatment after surgery two cycles of chemotherapy are generally adequate. This has not been shown to cause long-term toxicities such as infertility or secondary leukaemias, which are potential complications of heavier treatment regimens used for progressive disease (Scholz and Holtl, 2003).

 

 

The advantage of using chemotherapy initially is that it reduces the pressure on intense follow-up following surgery and reassures patients that everything is being done to eradicate the disease.

 

 

Chemotherapy toxicities

 

 

In the short term chemotherapy can cause nausea, vomiting and potentially life-threatening bone marrow suppression, making individuals susceptible to neutropenic sepsis. Cisplatin is nephrotoxic and ototoxic.

 

 

Because of the high survival rate there is a substantial amount of research looking at long-term toxicities among patients. Toxicities need to be carefully considered when deciding to pursue adjuvant chemotherapy. Most long-term surveys have shown that 10-25% of survivors will have persistent physical symptoms following chemotherapy (Fossa, 2003).

 

 

Bleomycin is toxic to the lungs, causing fatal pneumonitis in 0.5-1% of patients. Risk factors for this include being older than 40 years, smoking and having a history of pulmonary disease and impaired renal function (Dearnley and Huddart, 2001).

 

 

Cisplatin may damage both peripheral and sensory nerves. It is also known to affect the auditory nerves, causing hearing problems. Long-term ototoxicity, including hearing loss and tinnitus, has been reported in 20-25% of patients (Fossa et al, 2003). Peripheral neuropathies resolve in 6-12 months in most cases.

 

 

Chemotherapy often causes azoospermia, which is reversible in 70-80% of cases (Dearnley and Huddart, 2001). In one study, 19.5% of patients had confirmed infertility after treatment (Rudberg et al, 2002). Sperm can be banked before chemotherapy or RLND.

 

 

Other long-term toxicities include an increased risk of cardiac events (Huddart et al, 2003) and a higher rate of second malignancies. Some survivors report sexual problems (Joly et al, 2002; Vaughn et al, 2002).

 

 

Seminomas - early stage
Seminomas have a cure rate of over 90% and with early disease this figure is closer to 100%. Seven in ten men with seminomas have stage I disease. Early stage seminomas are usually treated with adjuvant radiotherapy post-surgery because 15% of stage I or II tumours will have occult retroperitoneal nodal spread that can be cured with radiotherapy.

 

 

Adjuvant radiotherapy is generally well-tolerated. The most commonly reported long-term complication is peptic ulcer occurring in 1.6-7.6% of patients (Grossfeld et al, 1998). In addition there is a risk of second malignancies including primaries in the upper gastrointestinal tract and bladder, leukaemia and reduced fertility in the remaining testis (Jones and Vasey, 2003a).

 

 

Advanced disease and relapse
A small number of men with testicular cancer will present with metastatic disease. Similarly a small number will fail to respond to conventional therapy.

 

 

Pattern of metastasis of testicular cancer

 

 

Testicular cancer tumours can metastasise lymphatically or via the blood. The lymphatic drainage pattern for the testes follows the path of the gonadal veins. Lymphatic metastases from a tumour in the left testicle may be found in the retroperitoneum at the level of the left renal vein. Contralateral involvement is less common but may be found with increased tumour burden. Haematological spread is commonly to liver and lung.

 

 

Standard treatment for metastatic disease is chemotherapy using the BEP regimen, with an overall cure rate of 80% for patients with good prognostic features. There is no real consensus on management after failure of BEP. Ifosphamide has been used in salvage regimens as well as high-dose chemotherapy regimens with peripheral blood stem cell rescue. This approach remains experimental (Miki and Nakao, 2002).

 

 

For seminomatous tumours in the earlier stages of relapse (stage II), radiotherapy alone may be used. More advanced disease will also require chemotherapy incorporating regimens similar to those described above. Sometimes surgical resection of residual masses will follow or high dose chemotherapy and stem cell rescue may be used (Jones and Vasey, 2003b).

 

 

This article has been double-blind peer-reviewed.

 

 

For related articles on this subject and links to relevant websites see www.nursingtimes.net

 

 

Learning objectives
Each week Nursing Times publishes a guided learning article with reflection points to help you with your CPD. After reading the article you should be able to:

 

 

- Know the presenting symptoms for most testicular cancers;

 

 

- Gain an understanding of the two main subtypes of testicular cancer and how their management differs;

 

 

- Appreciate some of the toxicities associated with current management regimens;

 

 

- Understand some of the nursing challenges associated with this patient group.

 

 

Guided reflection
Use the following points to write a reflection for your PREP portfolio:

 

 

- Write about your area of work and why this article may be relevant;

 

 

- Consider the last time you encountered a patient affected by testicular cancer;

 

 

- Identify a piece of information from this article that may have

 

 

helped you manage that patient;

 

 

- Consider how you would use this information with your next patient;

 

 

- Explain how you will disseminate this information to your colleagues.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.